---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106235"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:09:36.358123+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Agenus Q2 net loss improves; Zydus deal adds $91M; BOT/BAL Phase 3 starts Q4 2025

## Summary
- Q2 revenue $25.7M; YTD net loss $56.4M vs $118.3M YoY; cash burn reduced to $45.8M from $76.4M.
- Zydus collaboration closing Q3 2025; $91M upfront capital to support development and regulatory activities.
- BOT/BAL: 42% two-year survival in refractory MSS CRC; FDA agreed to streamlined Phase 3 (BATTMAN) starting Q4 2025.
- Virtual stakeholder meeting on August 27, 2025 to review Q2 results and strategic progress.
- Noetik AI partnership started to refine patient selection via AI algorithms.

## SEC filing metadata
- accession: 0000950170-25-106235
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/0000950170-25-106235-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000095017025106235/agen-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106235
- JSON: https://secwatch.observer/filing/0000950170-25-106235.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106235.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.